

# Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies

Melanie Aureal, Milene Seauve, Soline Laplane, Jean-Christophe Lega, Natalia Cabrera, Fabienne Coury

## ▶ To cite this version:

Melanie Aureal, Milene Seauve, Soline Laplane, Jean-Christophe Lega, Natalia Cabrera, et al.. Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies. RMD Open, 2023, 9 (3), pp.e003064. 10.1136/rmdopen-2023-003064.

# HAL Id: hal-04627729 https://hal.science/hal-04627729v1

Submitted on 22 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers. L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

# RMD Open

Rheumatic & Musculoskeletal Diseases

**To cite:** Aureal M, Seauve M, Laplane S, *et al.* Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and meta-analysis of randomised controlled trials, open-label studies and observational studies. *RMD Open* 2023;**9**:e003064. doi:10.1136/ rmdopen-2023-003064

 Additional supplemental material is published online only. To view, please visit the journal online (http://dx.doi.org/10. 1136/rmdopen-2023-003064).

MA and MS are joint first authors.

Received 10 February 2023 Accepted 19 August 2023



© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

For numbered affiliations see end of article.

Correspondence to

Fabienne Coury; fabienne.coury-lucas@chulyon.fr

### ORIGINAL RESEARCH

Incidence of infections in patients with psoriatic arthritis and axial spondyloarthritis treated with biological or targeted disease-modifying agents: a systematic review and metaanalysis of randomised controlled trials, open-label studies and observational studies

Melanie Aureal <sup>(1)</sup>, <sup>1,2</sup> Milene Seauve, <sup>1,2</sup> Soline Laplane, <sup>1,2</sup> Jean-Christophe Lega, <sup>3,4</sup> Natalia Cabrera, <sup>5</sup> Fabienne Coury<sup>1,2,4,6</sup>

### ABSTRACT

**Objective** To estimate the incidence of infections among patients with psoriatic arthritis (PsA) or axial spondyloarthritis (axSpA), two distinct phenotypes included in the large group of spondyloarthritis (SpA), treated with tumour necrosis-factor-inhibitors, interleukin-17-inhibitors, Janus kinase-inhibitors, IL-23 or IL-12/23-inhibitors (IL-12/23i), phosphodiesterase 4-inhibitors or cytotoxic T-lymphocyte associated protein 4-Ig.

**Methods** A meta-analysis of randomised controlled trials (RCTs), open-label extension and observational studies was conducted. Serious infections were defined as infections that were life-threatening, required intravenous antibiotics and/or hospitalisation. Non-serious infections did not meet these severity criteria. The incidence rates (IR) were reported for each diagnosis by treatment class and study type using random-effect model to create a 95% Cl.

Results Among 23 333 PsA patients and 11 457 axSpA patients, there were 1.09 serious infections per 100 patient-years (PY) (95% CI 0.85 to 1.35) with similar IR in PsA (0.96 per 100 PY 95% CI 0.69 to 1.28) and axSpA (1.09 per 100 PY 95% CI 0.76 to 1.46). The IR was lower in RCTs (0.77 per 100 PY 95% CI 0.41 to 1.20) compared with observational studies (1.68 per 100 PY 95% CI 1.03 to 2.47). In PsA patients, the lowest IR value was observed with IL-12/23i (0.29 per 100 PY 95% CI 0.00 to 1.03). There were 53.0 non-serious infections per 100 PY (95% CI 43.47 to 63.55) in 7257 PsA patients and 5638 axSpA patients. The IR was higher in RCTs (69.95 per 100 PY 95% CI 61.59 to 78.84) compared with observational studies (15.37 per 100 PY 95% CI 5.11 to 30.97). Conclusion Serious infections were rare events in RCTs and real-life studies. Non-serious infections were common adverse events, mainly in RCTs. PROSPERO registration number CRD42020196711

### INTRODUCTION

Spondyloarthritis (SpA) is a group of inflammatory rheumatic diseases including distinct disorders with axial inflammation and/or peripheral arthritis, enthesitis or dactylitis. Axial SpA (axSpA) refer either to ankylosing spondylitis (AS) or non-radiographic axSpA (nr-axSpA) based on radiographic structural damage according to the modified New-York criteria. Psoriatic arthritis (PsA) is another subtype of SpA with skin inflammation associated to joint involvement.<sup>1</sup>

Six biologics or targeted (b/tsDMARD) modifying disease agents are currently prescribed in PsA or axSpA with large clinical efficacy in active disease, refractory to nonsteroid anti-inflammatory drugs (NSAID). These treatments act either by inhibiting an inflammatory cytokine or its receptor (tumour necrosis factor (TNF), interleukin (IL)-17, IL-23, IL-12/23), molecules involved in cell activation (cytotoxic T-lymphocyte associated protein 4 (CTLA4)) with CTLA4-Ig, or intracellular signal pathways (Janus kinase (JAK) and phosphodiesterase 4 (PDE4)).<sup>2 3</sup> TNF-inhibitors (TNFi), IL-17-inhibitors (IL-17i) and JAK-inhibitors (JAKi) are used in PsA and axSpA, whereas IL-23-inhibitors (IL-23i), IL-12/23-inhibitors (IL-12/23i), PDE4inhibitors (PDE4i) and CTLA4-Ig are only used in PsA due to their lack of efficacy on the axial symptoms.

### WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ While the risk of infections in patients with rheumatoid arthritis or psoriasis treated with biological or targeted disease-modifying agents (b/tsDMARDs) has been extensively studied, there is limited research on the incidence of serious and non-serious infections in patients with spondyloarthritis, including psoriatic arthritis (PsA) and axial spondyloarthritis (axSpA).

### WHAT THIS STUDY ADDS

- ⇒ This meta-analysis provides an assessment of the incidence rates of serious and non-serious infections, both overall and stratified by diagnosis (PsA or axSpA), for each class of treatment in randomised trials (RCTs), open-label extensions and observational studies.
- ⇒ Serious infections were rare events in patients with PsA or axSpA. In observational studies, the incidence tended to be higher compared with RCTs. The lowest incidence rate was observed with the use of IL-12/23 inhibitors (IL-12/23i) and phosphodiesterase 4 inhibitors, which were specifically used in patients with PsA.
- ⇒ Non-serious infections showed a trend of higher incidence in RCTs and were likely under-reported in observational studies.

# HOW THIS STUDY MIGHT AFFECT RESEARCH, PRACTICE OR POLICY

⇒ This meta-analysis reassures clinicians about prescription of b/tsD-MARD in patients with PsA or axSpA regarding the risk of serious infections. However, it is important to note that non-serious infections were common adverse events that could have an impact on patient management.

Apart from the efficacy, safety and tolerance are two important parameters for therapeutic choice. Infections are a known side effect of these molecules, consistent with their mechanisms of action on the pathways of inflammation. A distinction is made between two types of infections. Serious infections are usually defined as life threatening, requiring intravenous antibiotics or hospitalisation. In the absence of consensual definition, we chose to define non-serious infections (NSI) as any infection which do not meet the criteria of serious infections.<sup>4</sup> NSI may include upper respiratory tract infections, influenza syndromes, nasopharyngitis, urinary tract infections, gastrointestinal infections, herpes infections, opportunistic infections, candida infections and skin infections. Although NSI are not life-threatening, their occurrence could be responsible for poor treatment compliance.<sup>5</sup>

Most of the data on the risk of infection in patients treated with b/tsDMARD are known from their use in other inflammatory diseases such as rheumatoid arthritis or psoriasis. However, characteristics of patients differ from one inflammatory disease to another, particularly in terms of age, comorbidities, pathophysiology of rheumatic diseases and associated treatments. Thus, it is difficult to extrapolate safety data from different populations.

Here, we present a meta-analysis to explore the incidence rate (IR) of serious and NSI in patients with SpA including PsA and axSpA stratified by diagnosis and according to class of treatment and study design (randomised controlled trials (RCTs), open-label extension (OLE) and observational studies).

### **MATERIAL AND METHODS**

### Literature research and study selection

The databases PubMed and Cochrane Central Register of Controlled Trial (CENTRAL) were searched from their date of inception to 30 March 2021, using a predefined search equation (online supplemental table 1). When necessary, additional studies were identified through hand searching.

The study was performed according to the Preferred Reporting the Items for Systematic Review and Meta-Analysis (PRISMA) statement for RCTs and OLE and in agreement with current recommendations of metaanalysis of observational studies in epidemiology group (MOOSE group) for observational studies (online supplemental table 2).

Three authors (MA, MS and SL) independently assessed titles and abstracts to identify relevant studies for inclusion. Discrepancies were discussed and when necessary, a fourth reviewer (FC-L) resolved any disagreements. The full text of the studies was obtained when necessary to confirm inclusion.

### **Inclusion criteria**

The studies were included if they: (1) investigated the number of serious infections defined as life-threatening, requiring intravenous antibiotics or hospitalisations or NSI defined as any event coded in the MedDRA SOC Infection and Infestation (MedDRA or Medical Dictionary for Regulatory Activities https://www.meddra.org) in RCTs and OLE and defined as any infection which do not meet the criteria of serious infections in observational studies; (2) involved patients with AS fulfilling modified New-York criteria, nr-AxSpA fulfilling Assessment of SpondyloArthritis International Society classification criteria for PsA and axSpA fulfilling Classification Criteria for Psoriatic Arthritis and (3) included patients treated with bDMARD or tsDMARD (TNF inhibitors(TNFi): etanercept, infliximab, golimumab, adalimumab and certolizumab pegol; IL-17i: secukinumab, ixekinumab, bimekizumab and brodalumab; IL-23i: ustekinumab, guselkumab and risankizumab; CTLA4-Ig: abatacept; JAKi: tofacitinib, upadacitinib and filgotinib; PDE4i: apremilast).

Studies with other design than RCTs, OLE or observational studies, such as mixed data of several pathologies other than AS, nr-AxSpA or PsA and studies in other languages than English were excluded. In addition, OLE should comprise RCTs data to be included.

### Data extraction and quality assessment

The following data were independently extracted by two authors (MA and MS) for each study: NCT (National Clinical Trial) number, year of publication, study design, country, pathology, population description, type and dose of b/tsDMARD, follow-up time, characteristics of population (sex, age, disease duration, disease activity, C-reactive protein, body mass index, concomitant treatment, previous biological therapy and smoking status), number of serious infections and number of NSI. The included studies used a variety of methods to report incidence. We used patient year (PY) when it was available in studies, or we calculated it if necessary.

If data were missing in the article, the corresponding authors were contacted by e-mail. Disagreements about data extraction were resolved by discussion with another independent author (FC-L). Revised Cochrane riskof-bias tool for randomised trials (RoB V.2, www.riskofbias.info) was used to assess the quality of RCTs and the Newcastle-Ottawa Scale (NOS) was used to assess the quality of OLE and observational studies (online supplemental table 3).

### **Statistical analysis**

The IR of infections was separated into two major groups, according to whether these events were serious infections or NSI. Then, we performed subgroup analyses by dividing all studies according to study type and treatment class. Those analysis were stratified according to the disease (PsA, axSpA and SpA).

Forest plots were constructed from the extracted data to create a 95% CI using R V.3.4 with package 'meta' (V.4.9–2) and 'metafor' (V.2.0–0). The IR of events (serious or NSI) and their 95% CI were estimated using inverse variance method and Freeman-Tukey double arcsine transformation. IR was expressed in events per 100 PY. Heterogeneity was assessed using inconsistency index (I<sup>2</sup>). If substantial heterogeneity was observed (I<sup>2</sup>>50%), a random-effects model was used based on Hartung-Knapp adjustment. The planned subgroup analyses were the following: study design, class of treatment and disease.

### RESULTS

### **Search results**

The initial search strategy identified 379 citations on PubMed and 348 citations on CENTRAL of which 96 were included (60 RCTs, 20 OLEs and 16 observational studies). A total of 89 studies (56 RCTs, 19 OLEs and 14 observational studies) about serious infections (n=33 892 patients with 33 168 PY of follow-up; 849 events) and 55 studies (37 RCTs, 8 OLEs and 10 observational studies) about NSI (n=13 008 patients with 12 451 PY of follow-up; 5339 events) were included (figure 1, table 1). The characteristics of patients are available in online supplemental table 4.

### **Serious infections**

The IR of serious infections was estimated at 1.09 events per 100 PY (95% CI 0.85 to 1.35,  $I^2=67\%$ ) in patients with SpA (PsA and axSpA). The IRs were 1.68 per 100 PY (95% CI 1.03 to 2.47,  $I^2=91\%$ ) for observational studies, 1.48 per 100 PY (95% CI 1.26 to 1.72,

 $I^2 = 0\%$ ) for OLE and 0.77 per 100 PY (95% CI 0.41 to 1.20,  $I^2 = 24\%$ ) for RCT (figure 2).

For patients with PsA, the IR of was estimated at 0.96 per 100 PY (95% CI 0.69 to 1.28,  $I^2=52\%$ ). For patients with axSpA, the IR of was estimated at 1.09 per 100 PY (95% CI 0.76 to 1.46,  $I^2=28\%$ ) (figure 3).

In subgroup analysis by the rapeutic classes in PsA patients, the IRs were 1.36 per 100 PY (95% CI 0.72 to 2.16, I<sup>2</sup>=55%) with TNFi, 0.97 per 100 PY (95% CI 0.49 to 1.57, I<sup>2</sup>=47%) with IL-17i, 1.51 per 100 PY (95% CI 0.00 to 14.74, I<sup>2</sup>=31%) with JAKi, 0.29 per 100 PY (95% CI 0.00 to 1.03, I<sup>2</sup>=15%) with IL-12/23i and IL-23i, 0.38 per 100 PY (95% CI 0.00 to 1.19, I<sup>2</sup>=0%) with PDE4i and 1.71 per 100 PY (95% CI 0.00 to 43.38, I<sup>2</sup>=1%) with CTLA4-Ig (figure 4A).

In axSpA patients, the IRs were 1.24 per 100 PY (95% CI 0.78 to 1.77,  $I^2=28\%$ ) with TNFi, 1.20 per 100 PY (95% CI 0.59 to 1.96,  $I^2=40\%$ ) with IL-17i, 1.28 per 100 PY (95% CI 0.00 to 13.77,  $I^2=0\%$ ) with JAKi (figure 4B).

### **Non-serious infections**

The IR of NSI was estimated at 53.04 NSI per 100 PY (95% CI 43.47 to 63.55,  $I^2=99\%$ ) in patients with SpA (PsA or axSpA). The IRs were 69.95 per 100 PY (95% CI 61.59 to 78.84,  $I^2=84\%$ ) for RCTs, 41.91 per 100 PY (95% CI 21.85 to 68.41,  $I^2=99\%$ ) for OLE and 15.37 per 100 PY (95% CI 5.11 to 30.97,  $I^2=99\%$ ) for observational studies (figure 5).

Similar IR was found for patients with PsA (54.08 (95% CI 40.96 to 68.99,  $I^2$ =98%)) or with axSpA (58.02 per 100 PY (95% CI 44.79 to 72.94,  $I^2$ =98%)) (*data not shown*). Subgroup analyses by class of treatment in RCTs was not performed because it resulted in too few studies in each subgroup.

### **Quality assessment**

Concerning the quality assessment, 58% of RCTs were judged as low risk, 42% of RCTs were judged with some concerns and none of the RCTs included were judged as high risk (online supplemental table 9).

The mean NOS score in observational studies was 5.9 ranging from four to seven stars, with four stars in one study,<sup>6</sup> five stars in five studies,<sup>7–11</sup> six stars in four studies<sup>12–15</sup> and seven stars in six studies.<sup>16–21</sup>

For serious infections in observational studies, metaregression analyses did not reveal any significant association; therefore, the source of heterogeneity could not be clearly identified (see online supplemental tables 5 and 6). The visual inspection of funnel plot and Egger's regression test (p<0.004) were in favour of small effect studies (online supplemental figure 1).

For NSI, meta-regression analyses did not reveal any significant association; therefore, the source of heterogeneity could not be clearly identified (see online supplemental tables 7 and 8). The visual inspection of funnel plot was in favour of effect studies (online supplemental figure 2).




Figure 1 Flowchart. axSpA, axial spondyloarthritis; PsA, psoriatic arthritis; RCT, randomised controlled trial; OLE, open-label extension.

### DISCUSSION

This large meta-analysis suggests that serious infections are rare events in the population of patients with PsA and axSpA treated with different classes of b/tsDMARD. For every 100 patients with SpA and treated with b/ tsDMARD, we reported a rate of 1.09 serious infections and 53.0 NSI. In our study, the IRs of serious and NSI were similar in patients with PsA and axSpA.

We choose to focus our study on the IR of infections to describe the absolute risk of infection in the population of patients with PsA or axSpA treated with b/tsDMARD. Indeed, while physicians and patients have a better understanding of the differences in risk when results are presented as absolute risk rather than relative risk, few studies in the literature have focused on the assessment of this absolute risk in population of patients with PsA and axSpA.<sup>22 23</sup>

Compared with rheumatoid arthritis, there is a trend toward a lower IR of serious infections in patients with PsA and axSpA. In fact, a meta-analysis including 66 RCTs and 22 OLEs, estimated the IR of serious infections at 4.90 per 100 PY in patients with rheumatoid arthritis treated with TNFi and 3.04 per 100 PY with CTLA4-Ig.<sup>24</sup> In observational registries, IR of serious infections varies between 3.1 and 6.4 infections per 100 PY.<sup>25-33</sup> Compared with psoriasis, the IR of serious infections in patients with PsA and axSpA appears to be similar. In a meta-analysis of RCTs, the IR of serious infections was estimated at 1.29 per 100 PY with IL-17i.<sup>34</sup> In trials PHOENIX 1, 2 and ACCEPT, the IR of serious infections in patients treated with ustekinumab was estimated at 1.4 per 100 PY.<sup>35</sup> In a nationwide cohort study from France involved data from the National Health Data System, IR of serious infections in was 25.0 (95% CI (23.8 to 26.2)) per 1000 PY among patients newly treated with biological treatment.<sup>36</sup>There is very limited data in the literature about IR of serious infections in patients without inflammatory disease or immunosuppressive treatment. In a large population-based study, Smollen et al found that patients with rheumatoid arthritis treated with any type of therapy (biological or not) have an IR of serious infections at 3.86

ล

TNF-inhibitors studies       Antoni (IMPACT)     2005     RCT phase 3       Van der Heijde     2014     RCT phase 3       Sieper (INFAST)     2014     RCT phase 3       Park (PLANETAS)     2016     OLE       Davis     2003     RCT phase 3       Mease     004     RCT phase 3       Braun     2011     RCT phase 3       Dougados     2014     RCT phase 3	c		Dose	Diagnosis	treatment group (n)	duration (weeks)	Outcome	
2005 2005 2014 2016 2003 2003 004 2011 2014	0						SI	ISN
(IMPACT) 2005 T Heijde 2005 T) 2014 (INFAST) 2014 LANETAS) 2016 2003 004 004 dos 2014	0							
r Heijde 2005 31) (INFAST) 2014 LANETAS) 2016 2003 2003 004 2011 dos 2014	nase 3	Infliximab	5 mg / kg / 6 w	PsA	52	16	×	
(INFAST) 2014 LANETAS) 2016 2003 004 2011 dos 2014	RCT phase 3	Infliximab	5 mg / kg / 6 w	AS	201	24	×	×
LANETAS) 2016 2003 004 2011 dos 2014	RCT phase 3 NCT00844805	Infliximab	5 mg / kg / 6 w	AS	105	28	×	×
2003 004 2011 dos 2014		Infliximab	5 mg / kg / 6 w	AS	174	102	×	×
004 2011 dos 2014	RCT phase 3	Etanercept	25 mg / 2 w	AS	138	24	×	
2011 dos 2014	RCT phase 3	Etanercept	25 mg / 2 w	PsA	101	24	×	
2014	RCT phase 3 NCT00247962	Etanercept	50 mg / 1 w	AS	379	16	×	
	RCT phase 3	Etanercept	50 mg / 1 w	Nr-AxSpA	106	12	×	×
Mease 2019 RCT pt	RCT phase 3 NCT02376790	Etanercept	50 mg / 1 w	PsA	567	48	×	
Davis 2007 OLE		Etanercept	25mg/2wand 50mg /1w	AS	257	192	×	×
Martin-Mola 2010 OLE		Etanercept	25 mg / 2 w and 50 mg / 1 w	AS	56	156	×	×
Inman (GO RAISE) 2008 RCT pl	RCT phase 3 NCT00265083	Golimumab	50 or 100 mg / 4 w	AS	278	24	×	×
Kavanaugh 2009 RCT pł (GOREVEAL)	RCT phase 3 NCT00265096	Golimumab	50 or 100 mg / 4 w	PsA	292	24	×	×
Kavanaugh 2017 RCT pł (GOVIBRANT)	RCT phase 3 NCT02181673	Golimumab	2mg / kg / 8w IV	PsA	240	24	×	×
Deodhar (GO ALIVE) 2018 RCT pl	RCT phase 3 NCT02186873	Golimumab	2mg / kg / 8w IV	AS	105	16	×	×
Kavanaugh (GO 2013 OLE REVEAL)		Golimumab	50 or 100 mg / 4 w SC	PsA	394	268	×	
Deodhar (GO RAISE) 2014 OLE		Golimumab	50 or 100 mg / 4 w SC	AS	353	268		×
Mease (ADEPT) 2005 RCT pt	RCT phase 3 NCT00195689	Adalimumab	40 mg / 2 w SC	PsA	151	24	×	×
Van der Heijde 2006 RCT pl (ATLAS)	RCT phase 3	Adalimumab	40 mg / 2 w SC	AS	208	24	×	×
Genovese 2007 RCT pł	RCT phase 3	Adalimumab	40 mg / 2 w SC	PsA	51	12	×	×
Huang 2012 RCT pt	RCT phase 3 NCT01114880	Adalimumab	40 mg / 2 w SC	AS	229	12	×	×
Sieper (ABILITY 1) 2013 RCT pt	RCT phase 3 NCT00939003	Adalimumab	40 mg / 2 w SC	Nr-AxSpA	91	12	×	×
Mease (ADEPT) 2008 OLE		Adalimumab	40 mg / 2 w SC	PsA	298	144	×	×
Van der Heijde 2009 OLE (ATLAS)		Adalimumab	40 mg / 2 w SC	AS	311	104	×	×
Van der Heijde 2018 OLE (ABILITY1)		Adalimumab	40 mg / 2 w SC	Nr-AxSpA	190	156	×	
Mease (RAPID-PsA) 2014 RCT pl	RCT phase3 NCT01087762	Certolizumabpegol	200mg / 2w or 400mg / 4w SC	PsA	273	24	×	×

### Spondyloarthritis

Landewe (RAPID- 20 AxSpA) 20 Kristensen 20 Saad 20 Modesti 20 Moura 20 Wallis 20		orady design registry number	Molecule	Dose	Diagnosis	group (n)	(weeks)	Outcome	
F	2014	RCT phase 3 NCT01087762	Certolizumabpegol	200 mg / 2 w or 400 mg / 4 w SC	AS	218	24	×	×
	2007	Observational	Several TNF-inhibitors	NA	PsA	261	105.1	×	
	2010	Observational	Several TNF-inhibitors	NA	PsA	596	156	×	
	2012	Observational	Several TNF-inhibitors	NA	AS/PsA	225	132.6	×	×
	2019	Observational	Several TNF-inhibitors	NA	SA	369	103	×	
	2014	Observational	Several TNF-inhibitors	NA	Nr-AxSpA	264	134.7	×	×
Ruberson Da Silva 20	2018	Observational	Several TNF-inhibitors	NA	PsA	122	24		×
	2018	Observational	Several TNF-inhibitors	NA	AS	122	221	×	×
Wroński 20	2019	Observational	Several TNF-inhibitors	NA	AS	103	72	×	×
IL-17 inhibitors									
Baeten 20	2013	RCT phase 2 NCT00809159	Secukinumab	10 mg / kg / 3 w IV	AS	24	28	×	×
McInnes 20	2014	RCT phase 2 NCT00809614	Secukinumab	10 mg / kg / 3 w IV	PsA	28	24	×	
Baeten (MEASURE 2) 20	2015	RCT phase 3 NCT01649375	Secukinumab	150 or 75 mg / 4 w SC	AS	145	16		×
Mease (FUTURE 1) 20	2015	RCT phase 3 NCT01392326	Secukinumab	150 or 75 mg / 4 w, atter IV loading infusion 10 mg / kg	PsA	406	24		×
McInnes (FUTURE 2) 20	2016	RCT phase 3 NCT01752634	Secukinumab	75 or 150 or 300 mg SC	PsA	299	16		×
Kivitz (MEASURE 4) 20	2018	RCT phase 3 NCT02159053	Secukinumab	150 mg / 4 w SC	AS	233	16	×	
Mease (FUTURE 5) 20	2018	RCT phase 3 NCT02404350	Secukinumab	150 or 300 mg / 4 w SC	PsA	664	24	×	
Huang (MEASURE 5) 20	2020	RCT phase 3 NCT02896127	Secukinumab	150 mg / 4 w SC	AS	305	16	×	
Deodhar (PREVENT) 20	2021	RCT phase 3 NCT02696031	Secukinumab	150 mg / 4 w SC	Nr-AxSpA	369	20	×	
McInnes (FUTURE 2) 20	2017	OLE	Secukinumab	75 or 150 or 300 mg SC	PsA	387	104	×	×
Kivitz (MEASURE 4) 20	2018	OLE	Secukinumab	150 mg / 4 w SC	AS	346	104	×	
Nash (FUTURE 3) 20	2018	OLE	Secukinumab	150 or 300 mg / 4w SC	PsA	406	52	×	
Baraliakos 20 (MEASURE 1)	2019	OLE	Secukinumab	150 or 75 mg / 4 w SC, after IV loading	AS	360	260	×	
4)	2019	OLE	Secukinumab	150mg / 4 w SC	PsA	334	104	×	
Huang (MEASURE 5) 20	2020	OLE	Secukinumab	150mg / 4 w SC	AS	453	52	×	
Van der Heijde 20 (FUTURE 5)	2020	OLE	Secukinumab	150or 300 mg / 4 w SC	PsA	255	52	×	
Deodhar 20	2021	OLE	Secukinumab	150mg / 4w SC	Nr-AxSpA	369	104	×	
Kiltz 20	2020	Observational	Secukinumab	MD	AS/PsA	1001	NA		×
Klavdianou 20	2020	Observational	Secukinumab	300mg / 4w SC	PsA	75	52	×	×
Ramonda 20	2020	Observational	Secukinumab	150 or 300 mg / 4 w SC	PsA	608	104	×	×
Mease (SPIRIT P1) 20	2017	RCT phase 3 NCT01695239	Ixekizumab	80 mg / 2 w / 4 w SC	PsA	210	24	×	×

6

Author (study name)	Year	Study design registry number	Molecule	Dose	Diagnosis	Patient in treatment group (n)	Study duration (weeks)	Outcome	
Nash (SPIRIT P2)	2017	RCT phase 3 NCT02349295	lxekizumab	80mg / 2 w / 4 w SC	PsA	245	24	×	×
Van der Heijde (COASTV)	2018	RCT phase 3 NCT02696785	lxekizumab	80mg / 2 w4 w SC	AS	164	16	×	×
Deodhar (COAST X)	2019	RCT phase 3 NCT02757352	lxekizumab	80mg / 2 w / 4 w SC	Nr-AxSpA	198	52	×	×
Deodhar (COAST W)	2019	RCT phase 3 NCT02696798	lxekizumab	80mg / 2 w / 4 w SC	AS	212	16	×	×
Dougados (COAST V/W)	2020	OLE	lxekizumab	80 mg / 2w / 4 w SC	AS	641	52	×	×
Orbai (SPIRIT P2)	2021	OLE	Ixekizumab	80 mg / 2w / 4 w SC	PsA	337	156	×	×
Ritchlin (BE ACTIVE)	2020	RCT phase 2 NCT02969525	Bimekizumab	16, 160 or 320 mg / 4 w SC	PsA	164	12	×	
Van der Heijde (BEAGILE)	2020	RCT phase 2 NCT02963506	Bimekizumab	16, 64, 160 or 320 mg / 4 w SC	AS	243	12	×	
Coates (BE ACTIVE)	2021	OLE	Bimekizumab	16, 64, 160 or 320 mg / 4 w SC	PsA	204	152	×	
Mease	2014	RCT phase 2 NCT01516957	Brodalumab	140 or 280 mg / 2w SC	PsA	113	12	×	
Mease (AMVISION 1–2)	2021	RCT phase 3 NCT02029495NCT02024646	Brodalumab	140 or 210 mg / 2 w SC	PsA	640	24	×	×
IL-23 inhibitors									
Gottlieb	2009	RCT phase 2 NCT00267956	Ustekinumab	90 or 63 mg / 1 w SC	PsA	76	12	×	×
McInnes (PSUMITT 1)	) 2013	RCT phase 3 NCT01009086	Ustekinumab	45 or 90 mg SC	PsA	409	16	×	×
Ritchlin	2014	RCT phase 2 NCT01077362	Ustekinumab	45 or 90 mg w0-w4, then every 12 w SC	PsA	207	24	×	×
Chimenti	2017	Observational	Ustekinumab	MD	PsA	65	104	×	×
Deodhar	2018	RCT phase 2 NCT02319759	Guselkumab	100 mg / 8 w SC	PsA	100	24	×	×
Deodhar (DISCOVER 1)	2020	RCT phase 3 NCT03162796	Guselkumab	100 mg / 4 w / 8 w SC	PsA	255	24	×	×
Mease (DISCOVER 2)	) 2020	RCT phase 3 NCT03158285	Guselkumab	100 mg / 4 w / w SC	PsA	493	24	×	×
McInnes	2021	OLE	Guselkumab	100 mg / 4 w / 8 w SC	PsA	731	52	×	
Baeten	2018	RCT phase 2 NCT02047110	Risankizumab	18, 90, 180 mg / 8 w SC	AS	119	16	×	×
CTLA4-Ig									
Mease	2011	RCT phase 2 NCT00534313	Abatacept	3or 10mg / kg (±2 initial doses of 30 mg / kg) IV / 28 days	PsA	128	24	×	
Mease (ASTRAEA) JAK-inhibitors	2017	RCT phase 3 NCT01860976	Abatacept	125 mg / 1 w SC	PsA	213	24	×	×
Gladman (OPAL	2017	RCT phase 3 NCT01882439	Tofacitinib	5mg or 10mg 2x / day	PsA	263	12	×	

# RMD Open: first published as 10.1136/rmdopen-2023-003064 on 15 September 2023. Downloaded from http://rmdopen.bmj.com/ on July 22, 2024 by guest. Protected by copyright.

7

Spondyloarthritis

Study design registry umber     Study design registry momber     Does     Diagnosis       Mease (DAL     2017     RCT phase 3 NCT0187668     To factinib     Emg or 10mg 2x / day     Pea       Wan der Heijde     2017     RCT phase 2 NCT0317668     To factinib     2.5 or 10mg 2x / day     Pea       Wan der Heijde     2018     RCT phase 2 NCT03176107     Fligotnib     2.0 on gray day     Pea       Wan der Heijde     2019     RCT phase 2 NCT03175487     Upadacitnib     2.0 on gray day     Pea       Wan der Heijde     2019     RCT phase 2 NCT03175487     Upadacitnib     20000 / day     Pea       Van der Heijde     2019     RCT phase 2 NCT03175487     Upadacitnib     20000 / day     Pea       Van der Heijde     2019     RCT phase 2 NCT03175487     Upadacitnib     20000 / day     Pea       Van der Heijde     2019     RCT phase 2 NCT03175477     Upadacitnib     20000 / day     Pea       Vertioner     2019     RCT phase 2 NCT03175477     Upadacitnib     20000 / day     Pea       Vertioner     2019     RCT phase 2 NCT0317703     Apemilast <t< th=""><th></th><th>Patient in</th><th>Study</th><th></th><th></th></t<>		Patient in	Study		
2017RCT phase 3 NCT01877668TotactinibEmg or 10mg 2x / dayR)2017RCT phase 2 NCT01786668Totactinib2, 5 or 10mg 2x / dayR)2018RCT phase 2 NCT03101670Filgotinib200mg / day2018RCT phase 2 NCT03117270Filgotinib200mg / day2019RCT phase 2 NCT03117270Filgotinib200mg / day2019RCT phase 2 NCT03178487Upadacitinib200mg / day2019RCT phase 2 NCT03178487Upadacitinib200mg / day2019RCT phase 2 NCT03178487Upadacitinib200mg / day2019RCT phase 2 NCT0117293Apremilast20mg 2x / day or 40mgACE2014RCT phase 3 NCT0117293Apremilast20or 30mg 2x / day2015RCT phase 3 NCT01212770Apremilast20or 30mg 2x / day2016RCT phase 3 NCT01212770Apremilast20or 30mg 2x / day2018RCT phase 3 NCT01212770Apremilast20or 30mg 2x / day2019RCT phase 3 NCT01212770Apremilast20or 30mg 2x / day2018RCT phase 3 NCT01212770Apremilast20or 30mg 2x / day2019RCT phase 3 NCT01212770Apremilast20or 30mg 2x / day2018RCT phase 3 N	Diagnosis	treatment group (n)	duration (weeks)	Outcome	
2017RCT phase 2NCT0178668Tofactimib2.5 or 10mg 2x / dayR)RCT phase 2 NCT03101670Filgotinib200 mg / day2018RCT phase 2 NCT03117270Filgotinib200 mg / day2019RCT phase 2 NCT03178487Upadacitinib200 mg / day2012RCT phase 2 NCT03178487Upadacitinib200 mg / day2012RCT phase 2 NCT01172938Apremilast200 mg / dayACE2014RCT phase 3 NCT01172938Apremilast2016RCT phase 3 NCT01212757Apremilast200 mg / day2018RCT phase 3 NCT01207423Apremi		211	12	×	
R)     2018     RCT phase 2 NCT0311270     Filgotinib     200mg / day       2018     RCT phase 2 NCT0311270     Filgotinib     200mg / day       2019     RCT phase 2 NCT03173487     Upadacitinib     200mg / day       2019     RCT phase 2 NCT03173487     Upadacitinib     200mg / day       2019     RCT phase 2 NCT03173487     Upadacitinib     200mg / day       2011     RCT phase 2 NCT03173487     Upadacitinib     200mg / day       ACE     2014     RCT phase 2 NCT01212767     Apremilast     200 r 30 mg 2 x / day       ACE     2016     RCT phase 3 NCT01212770     Apremilast     200 r 30 mg 2 x / day       2018     RCT phase 3 NCT01212770     Apremilast     200 r 30 mg 2 x / day       2018     RCT phase 3 NCT01307423     Apremilast     200 r 30 mg 2 x / day       2018     RCT phase 3 NCT01307423     Apremilast     200 r 30 mg 2 x / day       2018     RCT phase 3 NCT01307423     Apremilast     200 r 30 mg 2 x / day       2019     RCT phase 3 NCT01307423     Apremilast     200 r 30 mg 2 x / day       2019     RCT phase 3 NCT01307423     Apremilast		156	16	×	×
2018   RCT phase 2 NCT03117270   Filgotinib   200 mg / day     2019   RCT phase 2 NCT03178487   Upadacitinib   15 mg / day     2011   RCT phase 2 NCT03178487   Upadacitinib   15 mg / day     2012   RCT phase 2 NCT00456092   Apremilast   20 mg 2x / day or 40 mg     2012   RCT phase 2 NCT01172938   Apremilast   20 or 30 mg 2x / day     2015   RCT phase 3 NCT01172938   Apremilast   20 or 30 mg 2x / day     2016   RCT phase 3 NCT01212770   Apremilast   20 or 30 mg 2x / day     2018   RCT phase 3 NCT01212770   Apremilast   20 or 30 mg 2x / day     2018   RCT phase 3 NCT01307423   Apremilast   20 or 30 mg 2x / day     2018   RCT phase 3 NCT01307423   Apremilast   20 or 30 mg 2x / day     2018   RCT phase 3 NCT01307423   Apremilast   20 or 30 mg 2x / day     2018   RCT phase 3 NCT01307423   Apremilast   20 or 30 mg 2x / day     2019   NCT phase 3 NCT01307423   Apremilast   20 or 30 mg 2x / day     2019   Observational   Uptaktional, etanercept,   20 or 30 mg 2x / day     2019   Observational   Uptaktional, etanerce	PsA	65	16	×	×
2019RCT phase 2 NCT03178487Upadacitinib15 mg / day2012RCT phase 2 NCT00456092Apremilast20mg 2x / day or 40 mg4CE2014RCT phase 2 NCT0145093Apremilast20mg 2x / day or 40 mg4CE2014RCT phase 3 NCT01172938Apremilast200 30 mg 2x / day or 40 mg2016RCT phase 3 NCT01212757Apremilast200 30 mg 2x / day2018RCT phase 3 NCT01212770Apremilast200 30 mg 2x / day2018RCT phase 3 NCT01212770Apremilast200 30 mg 2x / day2018RCT phase 3 NCT01212773Apremilast200 30 mg 2x / day2018RCT phase 3 NCT0132743Apremilast200 30 mg 2x / day2018RCT phase 3 NCT01307423Apremilast200 30 mg 2x / day2018RCT phase 3 NCT01307423Apremilast200 30 mg 2x / day2019ObservationalUsterinumab, etamercept, apremilastNa2020ObservationalUsterinumab, etamercept, aprimumab, etamercept, adminumab, inflikimabNa2020ObservationalIntervinuab, usterinumab, etamercept, adminumab, inflikimabNa2020ObservationalIntervinuab, usterinumab, inflikimabNa	AS	58	12	×	×
2012RCT phase 2 NCT00456092Apremilast20mg 2x / day or 40mgACE2014RCT phase 3 NCT01172938Apremilast20mg 2x / day or 40mgACE2016RCT phase 3 NCT0117293Apremilast20or 30mg 2x / day or 40mg2)2016RCT phase 3 NCT01212757Apremilast20or 30mg 2x / day2)2016RCT phase 3 NCT01212770Apremilast20or 30mg 2x / day2)2018RCT phase 3 NCT01212770Apremilast20or 30mg 2x / day2)2018RCT phase 3 NCT0132773Apremilast20or 30mg 2x / day2)2018RCT phase 3 NCT01327423Apremilast20or 30mg 2x / day2)2018RCT phase 3 NCT01307423Apremilast20or 30mg 2x / day2)2018RCT p	AS	93	14	×	×
2012RCT phase 2 NCT00456092Apremilast20mg 2x / day or 40mg / dayACE2014RCT phase 3 NCT01172938Apremilast200 30mg 2x / day or 40mg2)2016RCT phase 3 NCT01212757Apremilast200 30mg 2x / day2)2016RCT phase 3 NCT01212770Apremilast200 30mg 2x / day2)2018RCT phase 3 NCT01307423Apremilast200 30mg 2x / day2)2019ObservationalUstekinumab, etanercept, andNa2)2020ObservationalInfiltiximabPacentolizumab, secukinumab, ustekinumab, etanercept, adaimurab, infiltiximabNa2)2020ObservationalInfiltiximabInfiltiximabInfiltiximab2)2020ObservationalInfiltiximabInfiltiximabInfiltiximab2)2020ObservationalInfiltiximabInfiltixi					
ACEDefendes 3 NCT01172938Apremilast20 or 30 mg 2x / day2)2016RCT phase 3 NCT01212757Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01212770Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01212770Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01212770Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01307423Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01307423Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01307423Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01307423Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01307423Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01307423Apremilast20 or 30 mg 2x / day2)2018RCT phase 3 NCT01307423Apremilast20 or 30 mg 2x / day2)2019ObservationalUsterinuab, etanetcept, or 30 mg 2x / day20200bservationalUsterinuab, etanetcept, or 30 mg 2x / day2)0bservationalUsterinuab, etanetcept, or 30 mg 2x		136	12	×	
2) 2016 RCT phase 3 NCT01212757 Apremilast 200r 30 mg 2x / day   E 3) 2016 RCT phase 3 NCT01212770 Apremilast 200r 30 mg 2x / day   2018 RCT phase 3 NCT01925768 Apremilast 30 mg 2x / day   2018 RCT phase 3 NCT01307423 Apremilast 200r 30 mg 2x / day   2019 RCT phase 3 NCT01307423 Apremilast 200r 30 mg 2x / day   2019 RCT phase 3 NCT01307423 Apremilast 200r 30 mg 2x / day   2019 RCT phase 3 NCT01307423 Apremilast 200r 30 mg 2x / day   2019 Doservational Ustekinumab, etanercept, and an adminumab, etanercept, and adminumab, etanercept, adminumab, attekinumab, attekinumab, attekinumab, attekinumab, attekinumab, atterinumab, att		336	24	×	
E 3)2016RCT phase 3 NCT01212770Apremilast200r 30 mg 2x / day2018RCT phase 3 NCT01925768Apremilast30 mg 2x / day2018RCT phase 3 NCT01307423Apremilast200r 30 mg 2x / day2019CobservationalUstekinumab, etanercept, inflikimab200r 30 mg 2x / day2020ObservationalUstekinumab, etanercept, adainnumab, etanercept, adainnumab, secukinumab, ustekinumab, etanercept, adainnumab, inflikimabNA		325	16	×	
2018 RCT phase 3 NCT01925768 Apremilast 30mg 2x / day   0 2018 RCT phase 3 NCT01307423 Apremilast 20or 30mg 2x / day   2019 Observational Ustekinumab, adalimumab, etanercept, infliximab 20or 30mg 2x / day   2020 Observational Ustekinumab, secukinumab, ustekinumab, infliximab NA		336	24	×	
0 2018 RCT phase 3 NCT01307423 Apremilast 20 or 30 mg 2x / day   2 2019 Observational Ustekinumab, etanercept, infliximab NA   2020 Observational Ixekizumab, secukinumab, ustekinumab, ustekinumab, etanercept, etanercept, odimumab, ustekinumab, ustekinumab, etanercept, etanercept, odimumab, etanercept, odimumab, infliximab NA	PsA	110	24	×	
2019ObservationalUstekinumab, adalimumab, etanercept, infliximabNA2020ObservationalIxekizumab, secukinumab, ustekinumab, adalimumab, certolizumab pegol, etanercept, golimumab, infliximab		350	24	×	
tchlin 2019 Observational Ustekinumab, adalimumab, etanercept, NA infliximab 2020 Observational Ixekizumab, secukinumab, ustekinumab, NA adalimumab, certolizumab pegol, etanercept, golimumab, infliximab					
2020 Observational Ixekizumab, secukinumab, ustekinumab, NA adalimumab, certolizumab pegol, etanercept, golimumab, infliximab	PsA	2041	256.4	×	
	PsA	5520	31.2	×	
Rahman 2020 Observational Golimumab, infliximab, ustekinumab NA PsA	PsA	462	416	×	×
Krabbe     2021     Observational     Abatacept, adalimumab, certolizumab     NA     AS/PsA       pegol, etanercept, golimumab, infliximab, secukinumab     nfliximab, secukinumab     nfliximab, secukinumab     nfliximab     nflix	AS/PsA	5387	52	×	

Author	n	Patient–Year		Events per 100 person–years	Incidence (%)	IC95%		Weight (random)
Study_type = RCT			1					
Antoni E. and al., 2005	2	16.00	-		▶ 12.50	[0.18; 37.67]	0.0%	0.2%
Baeten D. and al., 2013	1	12.92	-		→ 7.74	[0.00; 33.25]	0.0%	0.1%
Baeten D. and al., 2018	0	36.62	-		0.00	[0.00; 4.69]	0.1%	0.4%
Braun J. and al., 2011	0	116.62	+		0.18	[0.00; 1.84]	0.3%	0.9%
Cutolo M. and al., 2016	0	150.00			0.00	[0.00; 1.06]	0.4%	1.1%
Davis J. and al., 2003	2	63.69	-		3.45	[0.19; 9.79]	0.2%	0.6%
Deodhar A. and al., 2018 (1)	1	32.31	-		→ 4.28	[0.01; 14.57]	0.1%	0.3%
Deodhar A. and al., 2018 (2)	0	46.15	++		0.26	[0.00; 4.42]	0.1%	0.5%
Deodhar A. and al., 2019 (1)	1	198.00	+		0.16	[0.00; 1.69]	0.5%	1.3%
Deodhar A. and al., 2019 (2)	2	65.23	-		3.71	[0.46; 9.91]	0.2%	0.6%
Deodhar A. and al., 2020	0	117.69	+	-	0.10	[0.00; 1.73]	0.3%	0.9%
Deodhar A. and al., 2021	2	141.92	++		0.54	[0.00; 3.18]	0.4%	1.0%
Dougados M. and al., 2014	0	24.46	+		0.23	[0.00; 7.90]	0.1%	0.3%
Edwards C. and al., 2016	1	155.08			0.70	[0.00; 2.84]	0.4%	1.1%
Genovese M. and al., 2007	0	11.77	-		▶ 1.43	[0.00; 17.85]	0.0%	0.1%
Gladman D. and al., 2017	2	60.69		•	→ 3.66	[0.23; 10.32]	0.1%	0.6%
Gottlieb A. and al., 2009	0	17.54	-		▶ 1.09	[0.00; 12.14]	0.0%	0.2%
Huang F. and al., 2012	1	52.85	-		1.09	[0.00; 7.12]	0.1%	0.5%
Huang F. and al., 2020	4	93.85		,	→ 4.70	[1.30; 10.15]	0.2%	0.8%
Inman R. and al., 2008	2	128.31	-		1.62	[0.05; 4.76]	0.3%	1.0%
Kavanaugh A. and al., 2009	2	134.77			0.00	[0.00; 1.52]	0.3%	1.0%
Kavanaugh A. and al., 2014	2	155.08	-		0.88	[0.00; 3.42]	0.4%	1.1%
Kavanaugh A. and al., 2017	1	110.77			0.00	[0.00; 1.94]	0.3%	0.9%
Landewe R. and al., 2014	2	100.62	-	•	1.60	[0.00; 5.57]	0.2%	0.8%
McInnes I. and al., 2013	0	125.85			0.00	[0.00; 1.25]	0.3%	1.0%
McInnes I. and al., 2014	1	12.92	-		▶ 11.17	[0.30; 36.90]	0.0%	0.1%
Mease P. and al., 2004	0	46.62	+		0.22	[0.00; 4.32]	0.1%	0.5%
Mease P. and al., 2005	1	69.69	_	•	1.74	[0.00; 6.50]	0.2%	0.6%
Mease P. and al., 2011	2	59.08	-		• 4.16	[0.57; 11.00]	0.1%	0.6%
Mease P. and al., 2014 (1)	1	26.08			• 5.27	[0.01; 18.02]	0.1%	0.3%
Mease P. and al., 2014 (2)	4	126.00	1	•	3.12	[0.63; 7.17]	0.3%	1.0%
Mease P. and al., 2017 (1)	1	98.31	-		1.41	[0.01; 4.79]	0.2%	0.8%
Mease P. and al., 2017 (2)	3	96.92	1		3.50	[0.72; 8.27]	0.2%	0.8%
Mease P. and al., 2017 (3)	02	48.69 306.46	1		0.09	[0.00; 3.92]	0.1%	0.5%
Mease P. and al., 2018 (1) Mease P. and al., 2018 (2)	1	20.00			0.80 • 7.19	[0.11; 2.12] [0.17; 23.82]	0.8%	1.5% 0.2%
Mease P. and al., 2010 (2) Mease P. and al., 2019	16	523.38			2.67		1.3%	1.9%
Mease P. and al., 2019 Mease P. and al., 2020	4	227.54	1		1.96	[1.35; 4.37] [0.56; 4.21]	0.6%	1.3%
Mease P. and al., 2020 Mease P. and al., 2021	1	295.38	. 1		0.25	[0.00; 1.35]	0.7%	1.5%
Nash P. and al., 2017	3	113.08			2.69	[0.35; 6.77]	0.3%	0.9%
Nash P. and al., 2018	0	50.77			0.00	[0.00: 1.31]	0.1%	0.5%
Pavelka K. and al., 2017	0	46.15	-		0.48	[0.00; 4.68]	0.1%	0.5%
Ritchlin C. and al., 2014	õ	95.54			0.19	[0.00; 2.21]	0.2%	0.8%
Ritchlin C. and al., 2014	2	37.85			→ 5.51	[0.17; 16.17]	0.1%	0.4%
Schett G. and al., 2012	0	31.38	-		0.24	[0.00; 6.28]	0.1%	0.3%
Sieper J. and al., 2013	õ	21.00	-		0.49	[0.00; 9.60]	0.1%	0.2%
Sieper J. and al., 2014	2	56.54	-		2.67	[0.00; 9.69]	0.1%	0.5%
Wells A. and al., 2018	2	161.54	_		1.16	[0.00; 3.65]	0.4%	1.1%
van der Heijde D. and al., 2005	2	92.77	_		2.18	[0.04; 6.53]	0.2%	0.8%
van der Heijde D. and al., 2006	0	96.00	-		0.00	[0.00: 1.79]	0.2%	0.8%
van der Heijde D. and al., 2000	1	48.00			2.10	[0.00; 8.96]	0.1%	0.5%
van der Heijde D. and al., 2018 (1)	÷.	13.38	-		→ 10.72	[0.24; 35.57]	0.0%	0.2%
van der Heijde D. and al., 2018 (2)	2	50.46	_		> 2.72	[0.00; 10.54]	0.1%	0.5%
van der Heijde D. and al., 2019	0	25.04			0.91	[0.00; 8.65]	0.1%	0.3%
van der Heijde D. and al., 2020	1	56.08	-		2.38	[0.00; 8.31]	0.1%	0.5%
Fixed effect model	21		-		0.73	[0.44; 1.07]	12.6%	
Random effects model			-		0.77	[0.41; 1.20]		37.7%
Heterogeneity: $l^2 = 24\%$ , $\tau^2 = 0.0008$ , p	o = 0	0.06						

Figure 2 Forest plot of incidence rate of serious infections according to type of study. RCT, randomised controlled trial.

per 100 PY and estimated IR of SI of healthy individuals of general population at 1.25 per 100 PY. $^{37}$ 

To estimate the IR of infections, we have included many studies with various designs. We found a trend towards a higher IR of serious infections in observational studies than in RCTs. This could be explained by differences in population characteristics. In fact, despite RCTs are the gold standard as only randomisation and double blinding can allow for proper group comparison, these studies are of limited duration and often apply very strict inclusion criteria. Because of the longer time of follow-up and the inclusion of less selected patients sometimes with comorbidities, observational studies offer a valuable source of information for rare serious adverse events such as serious infections and might be more representative of the population encountered in daily practice.<sup>38 39</sup> In our study, mean treatment exposure was 6 months in RCTs, 2.4 years in OLE and 2.5 years in observational studies, which could imply an increase in the risk of infection with increasing duration of exposure to treatment. However, it is known from studies in rheumatoid arthritis, that risk of serious infections is increased in the first 6

months of treatment and higher IR of serious infections were reported for shorter study duration in rheumatoid arthritis.<sup>24 27 28</sup> On this issue, our results are mixed. On the one hand, there is a trend of a higher incidence of infection in OLE than in RCTs. This hypothesis is supported by an observational study in which mean serious infections onset time was 25.5 months in patients with AS.<sup>6</sup> However, we excluded many OLE during data extraction because of missing data or because they reported number of patients with serious infections instead of number of serious infections.<sup>40</sup> In this context, the population of OLE included in our study is not strictly comparable with that of RCTs and other confounding factors besides the duration of follow-up could explain differences in IR of serious infections. On the other hand, when we look at the IR of serious infections in RCTs and in their corresponding OLE, we also observe mixed results with some studies finding a higher IR of serious infections in RCTs<sup>41-46</sup> and other studies where the IR of serious infections seems higher in OLE.<sup>47-49</sup> More studies designed to evaluate the IR of serious infections over time in SpA are therefore needed. Also, in our meta-analysis, patients of

Author	n of SIp	person-year		person-years	Incidence (%)	IC95%	(fixed)	(rando
Pathology = PsA Mease P. et al., 2004	0	46.62			0.52	[0.00; 4.69]	0.1%	0.59
Antoni E. et al., 2005	2	16.00		,	15.37	[2.10; 40.64]	0.0%	0.29
Mease P. et al., 2005	1	69.69	-	· · · · · · · · · · · · · · · · · · ·	2.03	[0.02; 6.80]	0.2%	0.69
Kristensen L.E. et al., 2007	7 0	529.53	_	<u> </u>	1.36	[0.53; 2.56]	1.3%	1.99
Genovese M. et al., 2007 Mease P.J. et al., 2008	16	11.77 676.50		<u> </u>	1.79 2.43	[0.00; 18.26] [1.40; 3.75]	0.0% 1.7%	0.19
Gottlieb A. et al., 2009	0	17.54		,	1.35	[0.00; 12.42]	0.0%	0.29
Kavanaugh A. et al., 2009	2	134.77		÷	1.29	[0.00; 4.26]	0.3%	1.09
Saad A. et al., 2010	53	1776.20			2.96	[2.21; 3.82]	4.4%	2.49
Mease P. et al., 2011	2 0	59.08			4.16 0.70	[0.57; 11.01]	0.1%	0.69
Schett G. et al., 2012 McInnes I. et al., 2013	0	31.38 125.85	_	1	0.70	[0.00; 6.88] [0.00; 1.32]	0.1% 0.3%	0.39
Kavanaugh A. et al., 2013	19	1637.93	-		1.15	[0.68; 1.74]	4.0%	2.3
McInnes I. et al., 2014	1	12.92	_	,	11.27	[0.39; 37.00]	0.0%	0.19
Ritchlin C. et al., 2014	0	95.54	•		0.00	[0.00; 0.06]	0.2%	0.8
Kavanaugh A. et al., 2014 Mease P. et al., 2014 (1)	2 1	155.08 26.08			1.35 4.85	[0.04; 3.95] [0.00; 17.58]	0.4% 0.1%	1.19
Mease P. et al., 2014 (1)	4	126.00	_		3.22	[0.71; 7.27]	0.3%	1.0
Cutolo M. et al., 2016	0	150.00			0.00	[0.00; 0.98]	0.4%	1.19
Edwards C. et al., 2016	1	155.08	-		0.00	[0.00; 0.43]	0.4%	1.19
Chimenti M. et al., 2017	0	110.50	-		0.00	[0.00; 0.53]	0.3%	0.9
Nash P. et al., 2017 Gladman D. et al., 2017	3	113.08 60.69			2.59 3.92	[0.27; 6.66] [0.43; 10.58]	0.3%	0.9° 0.6'
Kavanaugh A. et al., 2017	ī	110.77	_		1.15	[0.00; 4.15]	0.3%	0.9
McInnes I.B. et al., 2017	12	751.30			1.25	[0.48; 2.29]	1.9%	2.0
Mease P. et al., 2017 (1)	1	98.31			0.60	[0.00; 3.84]	0.2%	0.8
Mease P. et al., 2017 (2)	3	96.92		· · · · · · · · · · · · · · · · · · ·	2.39	[0.03; 7.09]	0.2%	0.8
Mease P. et al., 2017 (3)	0	48.69	_		0.00	[0.00; 3.56]	0.1%	0.5
Nash P. et al., 2018 Wells A. et al., 2018	2	50.77 161.54			0.00 0.47	[0.00; 3.47] [0.00; 2.79]	0.1% 0.4%	0.5
Nash P. et al., 2018	8	444.44			0.98	[0.00, 2.79]	1.1%	1.8
Mease P. et al., 2018 (1)	2	306.46			0.44	[0.00; 1.72]	0.8%	1.5
Deodhar A.et al., 2018 (2)	0	46.15			0.00	[0.00; 2.32]	0.1%	0.5
Mease P. et al., 2018 (2)	1	20.00		·,	6.89	[0.01; 23.52]	0.0%	0.2
Richltin C.T. et al., 2019 Mease P. et al., 2019	111	6110.00 523.38			1.61	[1.29; 1.97]	15.1% 1.3%	2.6
Mease P. et al., 2019 Kivitz A.J. et al., 2019	16 9	523.38 558.40			2.65 0.98	[1.33; 4.35] [0.18; 2.19]	1.3%	1.9 1.9
Li X. et al., 2020	105	4159.00			1.61	[1.18; 2.10]	10.3%	2.5
Klavdianou K. et al., 2020	1	83.33	+		0.14	[0.00; 3.51]	0.2%	0.7
Rahman P. et al., 2020	11	979.00			0.36	[0.01; 1.05]	2.4%	2.2
Ramonda R. et al., 2020	6	1216.00			0.00	[0.00; 0.00]	3.0%	2.2
Ritchlin C. et al., 2020 Deodhar A. et al., 2020	2 0	37.85 117.69	_		4.69 0.00	[0.00; 15.28] [0.00; 0.05]	0.1%	0.4 0.9
Mease P. et al., 2020	4	227.54	·		1.57	[0.22; 3.80]	0.6%	1.3
Orbai A.M.et al., 2020	10	644.00		<u> </u>	0.94	[0.20; 2.04]	1.6%	2.0
van der Heidje D. et al., 2020	13	815.00			0.47	[0.02; 1.33]	2.0%	2.1
Mease P. et al., 2021	1	295.38	-		0.00	[0.00; 0.22]	0.7%	1.5
McInnes I.B. et al., 2021	9	608.00	•		0.00	[0.00; 0.13]	1.5%	1.9
Coates L.C. et al., 2021 Fixed effect model	4	210.53	-		1.29 1.12	[0.03; 3.66] [0.97; 1.29]	0.5% 61.4%	1.3
Random effects model Heterogeneity: $l^2 = 52\%$ , $\tau^2 = 0.0006$	i, p < 0.01		-		0.96	[0.69; 1.28]	-	56.9
Pathology = ax-SpA								
Davis J. et al., 2003	2	63.69		· · · · · · · · · · · · · · · · · · ·	3.51	[0.23; 9.85]	0.2%	0.6
van der Heijde D. et al., 2005	2	92.77		; , ,	2.31	[0.10; 6.66]	0.2%	0.8
van der Heijde D. et al., 2006 Davis JC. et al., 2007	0 9	96.00 587.00			0.00 1.16	[0.00; 1.85] [0.34; 2.33]	0.2%	0.8 1.9
Inman R. et al., 2008	2	128.31			1.01	[0.00; 4.06]	0.3%	1.0
van der Heidje D. et al., 2009	6	533.70			0.85	[0.15; 1.95]	1.3%	1.9
Martin-Mola E. et al., 2010	4	177.00	-	÷ • • • • • • • • • • • • • • • • • • •	2.44	[0.64; 5.33]	0.4%	1.2
Braun J. et al., 2011	0	116.62			0.00	[0.00; 1.23]	0.3%	0.9
Huang F. et al., 2012	1	52.85	-		0.89	[0.00; 6.83]	0.1%	0.5
Baeten D. et al., 2013 Sieper J. et al., 2013	1 0	12.92 21.00			10.41 0.71	[0.00; 36.14] [0.00; 9.90]	0.0% 0.1%	0.1
Wallis D. et al., 2014	10	683.86			1.06	[0.32; 2.11]	1.7%	2.0
Dougados M. et al., 2014	0	24.46		· · · · · · · · · · · · · · · · · · ·	0.35	[0.00; 8.13]	0.1%	0.3
Landewe R. et al., 2014	2	100.62		· · · · · · · · · · · · · · · · · · ·	1.98	[0.03; 5.98]	0.2%	0.8
Sieper J. et al., 2014	2	56.54			4.05	[0.33; 11.20]	0.1%	0.5
Park W. et al., 2016	4	341.31			1.01	[0.13; 2.50]	0.8%	1.6
Pavelka K. et al., 2017 van der Heijde D. et al., 2017	0	46.15 48.00			0.27	[0.00; 4.43] [0.00; 9.00]	0.1% 0.1%	0.5
Rusman T. et al., 2018	19	518.50		·	2.13	[0.00; 9.00]	1.3%	1.9
Baeten D. et al., 2018	0	36.62			0.41	[0.00; 5.68]	0.1%	0.4
Kivitz A.J. et al., 2018	8	692.00			1.14	[0.46; 2.11]	1.7%	2.0
van der Heidje D. et al., 2018	8	412.20	-	•	1.79	[0.65; 3.40]	1.0%	1.7
van der Heijde D. et al., 2018 (1) Deodhar A. et al., 2018 (1)	1	13.38 32.31			10.85 4.42	[0.35; 35.70] [0.08; 14.71]	0.0%	0.2
van der Heijde D. et al., 2018 (1)	2	50.46		1	4.42	[0.62; 12.84]	0.1% 0.1%	0.3
Moura C.S. et al., 2019	20	952.38			2.08	[1.25; 3.11]	2.4%	2.1
Wronski J. et al., 2019	0	142.62	•	<u>.</u>	0.08	[0.00; 1.43]	0.4%	1.0
van der Heijde D. et al., 2019	0	25.04	+	;	0.88	[0.00; 8.63]	0.1%	0.3
Barakliakos X. et al., 2019	14	1400.00			0.89	[0.43; 1.49]	3.5%	2.3
Deodhar A. et al., 2019 (1) Deodhar A. et al., 2019 (2)	1	198.00			0.67	[0.00; 2.35]	0.5%	1.3 0.6
Huang F. et al., 2019 (2)	2	65.23 93.85			3.68 4.71	[0.43; 9.88] [1.31; 10.15]	0.2%	0.6
van der Heijde D. et al., 2020	1	56.08			2.51	[0.02; 8.44]	0.2%	0.5
Dougados M. et al., 2020	10	641.00	_		1.56	[0.72; 2.70]	1.6%	2.0
Huang F. et al., 2020	9	457.10	-		2.00	[0.89; 3.53]	1.1%	1.8
Deodhar A. et al., 2021	2	141.92		+	1.68	[0.19; 4.53]	0.4%	1.0
Dehordar A. et al., 2021	12	369.00		·	3.15	[1.54; 5.29]	0.9%	1.7
Fixed effect model Random effects model Heterogeneity: $I^2 = 28\%$ , $\tau^2 = 0.0004$	, p = 0.06				1.02 1.09	[0.78; 1.28] [0.76; 1.46]	23.4%	38.
	, p = 0.00							
Pathology = SpA Modesti V. et al., 2012	12	763.36	_	•	1.50	[0.72; 2.54]	1.9%	2.1
	236	5387.00			4.36	[3.82; 4.94]	13.3%	2.5
Krabbe S. et al., 2021					3.94	[3.46; 4.45] [0.00; 47.34]	15.2%	
Krabbe S. et al., 2021 Fixed effect model								
Krabbe S. et al., 2021	, <i>p</i> < 0.01			• •	2.87	[0.00, 47.34]		4.6
Krabbe S. et al., 2021 Fixed effect model Random effects model	, <i>p</i> < 0.01			•	1.37	[1.24; 1.51]	100.0%	4.6

**Figure 3** Forest plot of incidence rate of serious infections according to diagnosis. axSpA, axial spondyloarthritis; PsA, psoriatic arthritis; SpA, spondyloarthritis.




Figure 4 Forest plot of incidence rate of serious infections according to PsA (A) or axSpA (B), subgroup analysis by class of treatment. axSpA, axial spondyloarthritis; PDE4, phosphodiesterase 4; PsA, psoriatic arthritis; TNF, tumour necrosis factor.

observational studies have longer disease duration and were treated with more concomitant drugs than in RCTs (concomitant corticoid was used by 28% of patients in observational studies and 14% of patients in RCTs). A prospective study assessing the IR of serious infections in a cohort of rheumatoid arthritis patients before the era of b/tsDMARD showed an increased risk in the presence of corticosteroid therapy (RR 2.2; 95% CI 1.5 to 3.4).<sup>50</sup> Another study showed a dose-dependent effect of corticosteroid therapy on the risk of severe pneumonia in patients with rheumatoid arthritis.<sup>51</sup> Another explanation is the more regular follow-up of patients in RCTs which benefit from closer monitoring and therefore more antibiotic prescriptions.

In the case of NSI, we found a trend towards a lower IR of NSI in observational studies compared with RCTs. Indeed, because these infections are not serious, patients are more likely to under-report them in studies with an observational design. It is not possible to compare the rates obtained in our study with existing data in the literature as the methods of collecting this adverse event vary from one study to another. In rheumatoid arthritis, a prospective observational cohort study BSBR-RA was estimated IR of NSI at 27 NSI per 100 PY from clinician questionnaires and patients diaries every 6 months for 3 years.<sup>52</sup> In a meta-analysis of 33 RCTs including patients with any inflammatory diseases treated with TFNi, IR of NSI range from 30 NSI per 100 PY with infliximab to eight NSI per 100 PY with etanercept.<sup>53</sup> RCTs therefore appear to be the best source for estimating the occurrence of NSI, as those are systematically recorded. It may be interesting to study whether NSI represent a risk factor for serious infections and could be used as a surrogate endpoint in RCTs.

Regarding therapeutic choice, the lowest IR of serious infections were found for IL-23i and PDE4i prescribed exclusively in PsA. This result is in agreement with a recent cohort study in patients with PsA or psoriasis showing that patients treated with ustekinumab had 1.3–3.0 times lower risk of hospitalised serious infections than patients initiating other biologics as TNFi.<sup>54</sup> Li *et al* reported in a cohort of patients with psoriasis (8010 PY)

Author	n	Patient-Yea	r	Events per 100 person–years	Incidence (%)	IC95%		Weight (random)
Study_type = RCT				1				
Baeten D. and al., 2013	18	12.92		· · · · · · · · · · · · · · · · · · ·	139.29	[81.51;211.94]	0.1%	1.5%
Baeten D. and al., 2015 (1)	75	76.62			97.89	[76.92; 121.37]	0.5%	1.8%
Baeten D. and al., 2015 (2)	46	44.62			103.10	[75.30; 135.21]	0.3%	1.8%
Baeten D. and al., 2018	37	36.62			101.05	[70.90; 136.45]	0.3%	1.7%
Deodhar A. and al., 2018 (1) Deodhar A. and al., 2018 (2)	12 16	32.31 46.15			38.22 35.66	[19.75; 62.64] [20.49; 54.99]	0.2% 0.3%	1.7% 1.8%
Deodhar A. and al., 2018 (2) Deodhar A. and al., 2019 (1)	81	198.00	_		41.13	[32.68; 50.56]	1.4%	1.0%
Deodhar A. and al., 2019 (1) Deodhar A. and al., 2019 (2)	57	65.23			86.61	[65.30; 110.86]	0.5%	1.8%
Deodhar A. and al., 2020	64	117.69			53.73	[41.17; 67.91]	0.8%	1.9%
Dougados M. and al., 2014	11	24.46		<u> </u>	46.74	[23.50: 77.83]	0.2%	1.7%
Genovese M. and al., 2007	9	11.77			79.90	[36.75; 139.37]	0.1%	1.5%
Gottlieb A. and al., 2009	27	17.54			156.36	[103.24; 220.44]	0.1%	1.6%
Huang F. and al., 2012	25	52.85		<del></del> .	46.23	[29.33; 66.76]	0.4%	1.8%
Inman R. and al., 2008	135	128.31			105.53	[ 88.49; 124.06]	0.9%	1.9%
Kavanaugh A. and al., 2009	103	134.77			72.61	[58.54; 88.11]	1.0%	1.9%
Kavanaugh A. and al., 2017	45	110.77			38.27	[27.22; 51.06]	0.8%	1.9%
Landewe R. and al., 2014	84	100.62			83.04	[66.09; 101.90]	0.7%	1.9%
Molnnes I. and al., 2013	74 82	125.85 92.00			58.81 89.30	[46.13; 73.02]	0.9% 0.7%	1.9% 1.8%
McInnes I. and al., 2016	68					[71.00; 109.70]		
Mease P. and al., 2005 Mease P. and al., 2014 (2)	114	69.69 126.00			97.84 90.82	[75.94; 122.49] [74.94; 108.23]	0.5% 0.9%	1.8% 1.9%
Mease P. and al., 2014 (2) Mease P. and al., 2015	120	186.46			64.03	[53.00; 76.08]	1.3%	1.9%
Mease P. and al., 2017 (1)	57	98.31		· · · · ·	57.99	[43.85; 74.09]	0.7%	1.9%
Mease P. and al., 2017 (2)	54	96.92			55.95	[42.01; 71.87]	0.7%	1.9%
Mease P. and al., 2018 (2)	14	20.00			72.08	[39.57; 114.19]	0.1%	1.6%
Mease P. and al., 2020	89	227.54			38.79	[31.07; 47.36]	1.6%	1.9%
Mease P. and al., 2021	171	295.38			57.34	[48.98; 66.36]	2.1%	1.9%
Nash P. and al., 2017	94	113.08			83.17	[67.17; 100.87]	0.8%	1.9%
Ritchlin C. and al., 2014	56	95.54			58.87	[44.45; 75.29]	0.7%	1.8%
Sieper J. and al., 2013	28	21.00			135.20	[89.95; 189.59]	0.1%	1.6%
Sieper J. and al., 2014	27	56.54		·	48.12	[31.64; 68.00]	0.4%	1.8%
van der Heijde D. and al., 2005	86	92.77			90.76	[72.15; 111.44]	0.7%	1.8%
van der Heijde D. and al., 2006 van der Heijde D. and al., 2017	66 32	96.00 48.00			69.05 67.54	[53.40; 86.70] [46.26; 92.81]	0.7% 0.3%	1.8% 1.8%
van der Heijde D. and al., 2017 van der Heijde D. and al., 2018 (1)	7	13.38			55.90	[22.99; 103.15]	0.3%	1.5%
van der Heijde D. and al., 2018 (2)	33	50.46			66.32	[45.74; 90.70]	0.4%	1.8%
van der Heijde D. and al., 2019	19	25.04		· · · · · · · · · · · · · · · · · · ·	77.43	[46.70; 115.83]	0.2%	1.7%
Fixed effect model					65.22	[ 62.41; 68.09]	22.5%	
Random effects model Heterogeneity: $I^2 = 84\%$ , $\tau^2 = 0.0158$ , p	0 < 0.0	01		-	69.95	[61.59; 78.84]		65.9%
Study_type = Observational	~				0.54		0.001	
Chimenti M. and al., 2017	9	110.50 938.90	+	i i	8.51	[ 3.92; 14.85]	0.8% 6.7%	1.9% 1.9%
Kiltz U. and al., 2020 Klavdianou K. And al., 2020	21 6	83.33			2.15 7.74	[ 1.28; 3.21] [ 2.90; 14.88]	0.6%	1.9%
Modesti V. and al., 2012	30	763.36			3.95	[ 2.66; 5.50]	5.4%	1.9%
Rahman P. and al., 2020	380	979.00			38.34	[34.54; 42.35]	7.0%	1.9%
Ramonda R. and al., 2020	72	1216.00	0		5.11	[ 3.82; 6.55]	8.6%	1.9%
Ruberson Da Silva M. and al., 2018		56.31		· · · · · · · · · · · · · · · · · · ·	73.60	[52.89; 97.73]	0.4%	1.8%
Rusman T. and al., 2018	40	518.50	•		5.61	[ 3.46; 8.16]	3.7%	1.9%
Wallis D. and al., 2014	127	683.86		i i	17.77	[14.68; 21.15]	4.9%	1.9%
Wrooski J. and al., 2019	57	142.62			40.22	[30.48; 51.32]	1.0%	1.9%
Fixed effect model					10.92	[10.05; 11.82]	39.0%	
Random effects model Heterogeneity: $l^2 = 99\%$ , $\tau^2 = 0.0370$ , p	0 < 0.0	D1	-		15.37	[ 5.11; 30.97]		18.8%
Study_type = Open_label_extensi								
Davis JC. and al., 2007	642	587.00		1	108.92	[100.62; 117.54]	4.2%	1.9%
Deodhar A. and al., 2014	576	1819.31		<b>i</b>	31.17	[28.64; 33.81]	12.9%	1.9%
Dougados M. and al., 2020	252	641.00		•	38.36	[33.65; 43.36]	4.6%	1.9%
Martin-Mola E. and al., 2010	37	177.00			17.61	[11.45; 24.90]	1.3%	1.9%
Mease P.J. and al., 2008	521	676.50		-	76.10	[ 69.63; 82.86]	4.8%	1.9%
Orbai A.M.and al., 2020	213	644.00		•	31.19	[26.89; 35.78]	4.6%	1.9%
Park W. and al.,2016	53	341.31	-		15.60	[11.68; 20.08]	2.4%	1.9%
van der Heidje D. and al., 2009	213	533.70			39.65	[34.47; 45.20]	3.8%	1.9%
Fixed effect model					43.02	[ 41.29; 44.79]	38.5%	15.00/
Random effects model Heterogeneity: $I^2 = 99\%$ , $\tau^2 = 0.0387$ , p	0 < 0.0	01		-	41.91	[21.85; 68.41]		15.2%
Fixed effect model					31.25	[ 30.33; 32.20]	100.0%	
Random effects model				-	53.04	[ 43.47; 63.55]		100.0%
Heterogeneity: $I^2 = 99\%$ , $\tau^2 = 0.0694$ , p	0 = 0							
			0 20	40 60 80 100 120 140				

Figure 5 Forest plot of incidence rate of non-serious infections according to type of study. RCT, randomised controlled trial.

or PsA (4159 PY of follow-up) that patients treated with an IL-23i were less likely to display a hospitalised serious infections than patients treated with a TNFi.<sup>12</sup> In a metaanalysis of patient with psoriasis, the rate of overall adverse event including serious infections was significantly higher in biologics targeting the IL-17 compared with biologics targeting IL-23.<sup>55</sup> The IR of serious infections with TNFi in axSpA was estimated at 1.24 events per 100 PY. To the best of our knowledge, only one other meta-analysis of nine RCTs estimated the IR of serious infections with TNFi at 1.9 per 100 PY.<sup>56</sup> The lower rate of serious infections in this study could be explained by the inclusion of more recent publications in which the population benefited of the current European Alliance of Associations for Rheumatology recommendations of vaccination against influenza and pneumococcal disease and systematic pretherapeutic assessment of infection. In SpA, IR of serious infections were similar with TNFi (1.29 events per 100 PY), IL-17i (1.05 events per 100 PY) and JAKi (1.30 events per 100 PY). Those results are in line with observational studies included in our meta-analysis which evaluated risk of infection in patients with PsA or psoriasis treated with IL-17i or TNFi and found no significant difference regarding serious infections.

a recent observational study from the Nordic Countries suggest a higher risk of infection with secukinumab than TNFi in patients with SpA. The authors moderate this result as the crude excess risk seemed largely explained by more frequent secukinumab use in difficult-to-treat patients especially in patients older, with longer disease duration and who were not naïve from biologic (53% bionaive in TNF group vs 11% bionaive in secukinumab group).<sup>57</sup>

The main limitation of this meta-analysis was the substantial heterogeneity in observational studies, without source identification. Higher methodological and clinical heterogeneity is often expected in MOOSE compared with RCTs. Subgroup analyses did not improve the heterogeneity and meta-regression analyses for year of publication, duration of follow-up and number of patients with concomitant corticoid, NSAID or conventional synthetic DMARD were not significant in univariate analysis. This high heterogeneity could explain a part of the funnel plot asymmetry. Moreover, we could not exclude publication bias given the results of Egger's regression test and funnel plot, although the asymmetry of funnel plot may be related to the smaller cohorts being at increased risk of infection or, in observational studies, related to the easier publication of positive studies with significant results.

We attempted to estimate the IR as precisely as possible using data from various study designs. However, we found a lack of large observational studies evaluating the IR of serious infections in this population, in particular in national cohorts, unlike in rheumatoid arthritis. Because of the absence of a control group in observational studies, it was not possible to evaluate the relative risk of serious and NSI in those studies. We did not include studies concerning biosimilars because our search equation was based on the international non-proprietary nomenclature of drugs, whereas biosimilars have names specific to each laboratory that develops them. Only one study with a biosimilar was included (PLANETAS OLE) as the biosimilar was compared with the reference originator infliximab arm and only this last one was included in our meta-analysis.

### CONCLUSION

Our meta-analysis highlights that serious infections are rare events in the specific population of patients with PsA or axSpA treated with b/tsDMARD despite a trend of a higher incidence in observational studies compared with RCTs.

NSI were frequent in RCTs although their impact is currently poorly studied in the literature. The impact of the frequent finding of NSI in patients treated with b/ tsDMARD, mainly in RCTs studies, needs to be explored.

### Author affiliations

<sup>1</sup>Departement of rheumatology, Lyon-Sud Hospital Hospices civiles de Lyon, Pierre-Benite, France

<sup>2</sup>University of Lyon, University of Lyon 1 Claude Bernard, Lyon, Rhône-Alpes, France

<sup>3</sup>Department of Internal and Vascular Medicine, Hospices Civils de Lyon, Lyon, France

<sup>4</sup>Lyon Immunopathology Federation (LIFe), Hospices Civils de Lyon, Lyon, France <sup>5</sup>University of Lyon, Laboratoire de Biométrie et Biologie Évolutive UMR - CNRS 5558, Lyon, France

<sup>6</sup>University of Lyon, INSERM UMR 1033, Lyon, France

### Twitter Natalia Cabrera @ncabroj

Acknowledgements We wish to thank all patients who participated in studies included in our paper.

**Contributors** MA and MS equally contributed to this article. MA, MS and SL contributed to data collection. NC and J-CL contributed to the statistical analysis. MA and FC-L wrote the manuscript. All the authors participated in the interpretation of the data. All authors critically appraised the manuscript for important intellectual content and approved the final manuscript. FC-L is the guarantor for this manuscript.

**Funding** The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Not required.

Ethics approval Not applicable.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement All data relevant to the study are included in the article or uploaded as supplementary information.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

### ORCID iD

Melanie Aureal http://orcid.org/0000-0001-6905-8735

### REFERENCES

- 1 Claudepierre P, Wendling D, Breban M, et al. Ankylosing spondylitis, spondyloarthropathy, spondyloarthritis, or spondylarthritis: what's in a name? *Joint Bone Spine* 2012;79:534–5.
- 2 Coates LC, Corp N, van der Windt DA, et al. GRAPPA treatment recommendations: an update from the 2020 GRAPPA annual meeting. J Rheumatol 2021; jrheum.
- 3 Wendling D, Lukas C, Prati C, et al. 2018 update of French society for rheumatology (SFR) recommendations about the everyday management of patients with spondyloarthritis. *Joint Bone Spine* 2018;85:275–84.
- 4 International conference on Harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH harmonized tripartite guideline: guideline for good clinical practice. J Postgrad Med 2001;47:45–50.
- 5 Pan SMD, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. *Arthritis Rheum* 2009;61:560–8. 10.1002/art.24463 Available: http://doi.wiley.com/10. 1002/art.v61%3A5
- 6 Modesti V, Ramonda R, Ortolan A, *et al*. Infection relapse in Spondyloarthritis treated with biological drugs: a single-centre study. *Scand J Rheumatol* 2012;41:490–1.
- 7 da Silva MRR, Dos Santos JBR, Almeida AM, et al. Effectiveness and safety of anti-TNF in psoriatic arthritis patients in Brazil: a postincorporation analysis. J Comp Eff Res 2018;7:989–1000.
- 8 Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from

### **RMD** Open

the British society for rheumatology biologics register. *Rheumatology* (*Oxford*) 2010;49:697–705.

- 9 Chimenti MS, Ortolan A, Lorenzin M, et al. Effectiveness and safety of Ustekinumab in Naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective Multicentric study. *Clin Rheumatol* 2018;37:397–405.
- 10 Wallis D, Thavaneswaran A, Haroon N, et al. Tumour necrosis factor inhibitor therapy and infection risk in axial spondyloarthritis: results from a longitudinal observational cohort. *Rheumatology (Oxford)* 2015;54:152–6.
- 11 Rusman T, Ten Wolde S, Euser SM, *et al.* Gender differences in retention rate of tumor necrosis factor alpha inhibitor treatment in ankylosing spondylitis: a retrospective cohort study in daily practice. *Int J Rheum Dis* 2018;21:836–42.
- 12 Li X, Andersen KM, Chang H-Y, et al. Comparative risk of serious infections among real-world users of Biologics for psoriasis or psoriatic arthritis. Ann Rheum Dis 2020;79:285–91.
- 13 Wroński J, Fiedor P, Głuszko P. Adverse events in patients with ankylosing spondylitis treated with TNF inhibitors: a cross-sectional study. Int J Clin Pharm 2019;41:864–71.
- 14 Ritchlin CT, Stahle M, Poulin Y, et al. Serious infections in patients with self-reported Psoriatic arthritis from the psoriasis longitudinal assessment and Registry (PSOLAR) treated with biologics. *BMC Rheumatol* 2019;3:52.
- 15 Klavdianou K, Lazarini A, Grivas A, et al. Real life efficacy and safety of Secukinumab in biologic-experienced patients with psoriatic arthritis. Front Med 2020;7:288.
- 16 Kristensen LE, Gülfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish arthritis treatment group register. Ann Rheum Dis 2008;67:364–9.
- 17 Kiltz U, Sfikakis PP, Gaffney K, et al. Secukinumab use in patients with moderate to severe psoriasis, psoriatic arthritis and ankylosing spondylitis in real-world setting in Europe: baseline data from SERENA study. Adv Ther 2020;37:2865–83.
- 18 Ramonda R, Lorenzin M, Carriero A, et al. Effectiveness and safety of Secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. *RMD Open* 2021;7:e001519.
- 19 Krabbe S, Grøn KL, Glintborg B, et al. Risk of serious infections in arthritis patients treated with biological drugs: a matched cohort study and development of prediction model. *Rheumatology (Oxford)* 2021;60:3834–44.
- 20 Moura CS, Rahme E, Maksymowych WP, et al. Use of diseasemodifying anti-rheumatic or anti-tumour necrosis factor drugs and risk of hospitalized infection in ankylosing spondylitis. *Scand J Rheumatol* 2019;48:121–7.
- 21 Rahman P, Arendse R, Khraishi M, et al. Long-term effectiveness and safety of Infliximab, Golimumab and Ustekinumab in patients with psoriatic arthritis from a Canadian prospective observational registry. BMJ Open 2020;10:e036245.
- 22 Gigerenzer G, Gaissmaier W, Kurz-Milcke E, et al. Helping doctors and patients make sense of health Statistics. *Psychol Sci Public Interest* 2007;8:53–96.
- 23 Zipkin DA, Umscheid CA, Keating NL, et al. Evidence-based risk communication: a systematic review. Ann Intern Med 2014;161:270–80.
- 24 Strand V, Ahadieh S, French J, *et al.* Systematic review and metaanalysis of serious infections with tofacitinib and biologic diseasemodifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. *Arthritis Res Ther* 2015;17:362.
- 25 Cecconi M, Ranza R, Titton DC, et al. Incidence of infectious adverse events in patients with rheumatoid arthritis and spondyloarthritis on biologic drugs—data from the brazilian registry for biologics monitoring. J Clin Rheumatol 2020;26:73–8.
- 26 Zink A, Manger B, Kaufmann J, et al. Evaluation of the RABBIT risk score for serious infections. *Ann Rheum Dis* 2014;73:1673–6.
- 27 Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: results from the British society for rheumatology biologics register. Arthritis Rheum 2006;54:2368–76.
- 28 Askling J, Fored CM, Brandt L, et al. Time-dependent increase in risk of Hospitalisation with infection among Swedish RA patients treated with TNF antagonists. Ann Rheum Dis 2007;66:1339–44.
- 29 Pérez-Sola MJ, Torre-Cisneros J, Pérez-Zafrilla B, et al. Infections in patients treated with tumor necrosis factor antagonists: incidence, etiology and mortality in the BIOBADASER registry. *Med Clin (Barc)* 2011;137:533–40.
- 30 Strangfeld A, Eveslage M, Schneider M, et al. Treatment benefit or survival of the fittest: what drives the time-dependent decrease in

serious infection rates under TNF inhibition and what does this imply for the individual patient *Ann Rheum Dis* 2011;70:1914–20.

- 31 Atzeni F, Sarzi-Puttini P, Botsios C, *et al.* Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. *Autoimmun Rev* 2012;12:225–9.
- 32 Komano Y, Tanaka M, Nanki T, *et al.* Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the registry of Japanese rheumatoid arthritis patients for longterm safety. *J Rheumatol* 2011;38:1258–64.
- 33 Harrold LR, Griffith J, Zueger P, et al. Longterm, real-world safety of Adalimumab in rheumatoid arthritis: analysis of a prospective USbased Registry. J Rheumatol 2020;47:959–67.
- 34 Loft ND, Vaengebjerg S, Halling A -S., et al. Adverse events with IL-17 and IL-23 inhibitors for psoriasis and Psoriatic arthritis: a systematic review and meta-analysis of phase III studies. J Eur Acad Dermatol Venereol 2020;34:1151–60. 10.1111/jdv.16073 Available: https://onlinelibrary.wiley.com/toc/14683083/34/6
- 35 Ghosh S, Gensler LS, Yang Z, et al. Ustekinumab safety in psoriasis, psoriatic arthritis, and Crohn's disease: an integrated analysis of phase II/III clinical development programs. Drug Saf 2019;42:809.
- 36 Penso L, Dray-Spira R, Weill A, et al. Association between biologics use and risk of serious infection in patients with psoriasis. JAMA Dermatol 2021;157:1056–65.
- 37 Smolen JS, Aletaha D, Barton A, et al. Rheumatoid arthritis. Nat Rev Dis Primers 2018;4:18001.
- 38 Van Spall HGC, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA 2007;297:1233–40.
- 39 Sedrak MS, Freedman RA, Cohen HJ, et al. Older adult participation in cancer clinical trials: a systematic review of barriers and interventions. CA Cancer J Clin 2021;71:78–92.
- 40 Sterne JAC, Sutton AJ, Ioannidis JPA, et al. Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials. *BMJ* 2011;343.
- 41 Kavanaugh A, McInnes IB, Mease P, et al. Clinical efficacy, radiographic and safety findings through 5 years of subcutaneous golimumab treatment in patients with active psoriatic arthritis: results from a long-term extension of a randomised. *Ann Rheum Dis* 2014;73:1689–94.
- 42 Huang F, Sun F, Wan W-G, et al. Secukinumab provided significant and sustained improvement in the signs and symptoms of ankylosing spondylitis: results from the 52-week, phase III Chinacentric study, MEASURE 5. Chin Med J (Engl) 2020;133:2521–31.
- 43 van der Heijde D, Mease PJ, Landewé RBM, et al. Secukinumab provides sustained low rates of radiographic progression in psoriatic arthritis: 52-week results from a phase 3 study, FUTURE 5. Rheumatology (Oxford) 2020;59:1325–34.
- 44 Orbai A-M, Gratacós J, Turkiewicz A, et al. Efficacy and safety of Ixekizumab in patients with psoriatic arthritis and inadequate response to TNF inhibitors: 3-year follow-up (SPIRIT-P2). *Rheumatol Ther* 2021;8:199–217.
- 45 Coates LC, Warren RB, Ritchlin CT, *et al.* Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from a phase 2B open-label extension study. *Ann Rheum Dis* 2021;80(Suppl 1):779–80.
- 46 Davis JC Jr, van der Heijde DM, Braun J, et al. Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 2008;67:346–52.
- 47 Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of Psoriatic arthritis: 2-year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). Ann Rheum Dis 2009;68:702–9.
- 48 van der Heijde D, Schiff MH, Sieper J, et al. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 2009;68:922–9.
- 49 Sieper J, van derD, Dougados M, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial Spondyloarthritis:results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis 2013;72:815–22.
- 50 Franklin J, Lunt M, Bunn D, et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. Ann Rheum Dis 2007;66:308–12.
- 51 Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. *Arthritis Rheum* 2006;54:628–34.

# 

### Spondyloarthritis

- 52 Bechman K, Halai K, Yates M, et al. Nonserious infections in patients with rheumatoid arthritis: results from the British society for rheumatology biologics register for rheumatoid arthritis. Arthritis Rheumatol 2021;73:1800–9. 10.1002/art.41754 Available: https:// onlinelibrary.wiley.com/toc/23265205/73/10
- 53 Dao KH, Herbert M, Habal N. Nonserious infections. Rheum Dis Clin North Am 2012;38:707–25.
- 54 Jin Y, Lee H, Lee MP, *et al*. Risk of hospitalization for serious infection after initiation of ustekinumab or other Biologics in patients with psoriasis or psoriatic arthritis. *Arthritis Care Res (Hoboken)* 2022;74:1792–805.
- 55 Cui L, Chen R, Subedi S, et al. "Corrigendum to "efficacy and safety of Biologics targeting IL-17 and IL-23 in the treatment of moderate-

to-severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials" [INT. Immunopharmacol. 62 (2018) 46-58]". *Int Immunopharmacol* 2018;64:432.

- 56 Fouque-Aubert A, Jette-Paulin L, Combescure C, *et al.* Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. *Ann Rheum Dis* 2010;69:1756–61.
- 57 Glintborg B, Di Giuseppe D, Wallman JK, *et al.* Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? an observational study from the Nordic countries. *Rheumatology* (*Oxford*) 2023;62:647–58.